Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18625310 | 0.87 | BRD4 (0.40) | BRD4ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL15549951 | 0.86 | MAPT (0.41) | CYP19A1ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL31290998 | 0.86 | CRHBP (0.39) | CYP19A1BRD4ALDH1A1MAPTKMT2A | |
| SCHEMBL31191034 | 0.86 | CRHBP (0.39) | CYP19A1BRD4ALDH1A1MAPTKMT2A | |
| SCHEMBL16875669 | 0.80 | MDM2 (0.42) | CYP19A1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL25357966 | 0.76 | ALDH1A1 (0.40) | CYP19A1BRD4ALDH1A1MAPTKMT2A | |
| SCHEMBL25359757 | 0.75 | CYP19A1 (0.58) | CYP19A1BRD4MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL8511034 | 0.75 | MAPT (0.49) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL16884431 | 0.73 | MAPT (0.35) | ALDH1A1MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL25357971 | 0.72 | CYP19A1 (0.39) | CYP19A1BRD4ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165225-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165225-A1 | Heterocyclic Flavone Derivatives, Compositions, and Methods Related Thereto | BDNF, NTRK2, RHOT2 | CYP19A1 374/4885BRD4 3636/4885ALDH1A1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.